CE Symposium - Oral Antiplatelet Therapies for Acute Coronary Syndromes and Best Practices

A CE Satellite Program taking place Thursday, May 2, 2013 at the 2013 PCNA 19th Annual Symposium from 8:00AM - 9:45AM at the Paris Las Vegas Hotel, General Session Ballroom, Las Vegas, NV.
By: CMEPlanet
SPRINGFIELD, N.J. - March 27, 2013 - PRLog -- Dual oral antiplatelet therapy, with aspirin and a P2Y12 receptor inhibitor, for the management of patients experiencing an acute coronary syndrome (ACS), has demonstrated significant improvements in the prevention of recurring major cardiovascular events versus aspirin alone. The realization that a significant number of ACS patients experience thrombotic outcomes while on dual antiplatelet therapy with aspirin and clopidogrel, together with the extensive research on clopidogrel resistance and the awareness that poor metabolizers of clopidogrel are associated with higher cardiovascular event rates following ACS or PCI, has provided the rationale for prasugrel and ticagrelor. While clopidogrel, prasugrel, and ticagrelor are all P2Y12 receptor inhibitors, they have distinct pharmacologic properties. Both prasugrel and ticagrelor have been studied separately against clopidogrel, on a background of aspirin therapy, in the setting of ACS; the study results have led to the inclusion of prasugrel and ticagrelor in ACS clinical practice guidelines.

After hospital discharge, ACS patients require efficient transitions of care to prevent the recurrence of major cardiovascular events. In addition to oral antiplatelet therapy after an ACS, a number of interventions and cardiometabolic goals (lifestyle and pharmacologic), based on clinical trial evidence and evolving clinical practice guidelines, are recommended to reduce the risk of another ischemic event, and patient compliance is critical. Therefore, in this program, Dr. Robert Kloner and Dr. Lynne Braun will describe the changing landscape of oral antiplatelet therapy for patients with ACS, and identify best practices in secondary prevention.

Register online at: http://www.pcna.net/symposium
You must be registered for the PCNA 19th Annual Symposium in order to attend.

Thursday, May 2, 2013
Registration and Breakfast: 8:00 AM - 8:45 AM
Symposium: 8:45 AM - 9:45 AM

General Session Ballroom
Paris Las Vegas Hotel
Las Vegas, NV


Lynne T. Braun, PhD, CNP, FAHA, FPCNA, FAAN
Professor of Nursing and Nurse Practitioner
Rush University College of Nursing
Chicago, Illinois

Robert A. Kloner, MD, PhD
Professor of Medicine
University of Southern California
Los Angeles, California

Visit http://www.pcna.net/symposium to register online.

Accreditation Statement

This educational activity is provided by the Preventive Cardiovascular Nurses
Association (PCNA). Multiple educational grants have been requested to support
this program. PCNA is approved as a provider of nurse practitioner continuing
education (CE) programs by the American Association of Nurse Practitioners
(AANP), provider number 030602. This program is accredited for 1 contact hour
of continuing education. This program was planned in accordance with AANP CE
Policies and Commercial Support Standards.

Supported by an educational grant from AstraZeneca Pharmaceuticals, LP.

Registration for the PCNA 19th Annual Symposium is required in order to attend.
For additional CME activities and online cme courses visit http://www.cmeplanet.com
Email:***@voxmedia.us Email Verified
Tags:Nursing Ce
Location:Springfield - New Jersey - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Voxmedia News
Most Viewed
Daily News

Like PRLog?
Click to Share